Type 2 myocardial infarction

Radovanović, Dragana; Pilgrim, Thomas; Seifert, Burkhardt; Urban, Philip; Pedrazzini, Giovanni; Erné, Paul

doi:10.2459/jcm.0000000000000504

Cited by 21 publications

(10 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among patients presenting to an ED with elevated cardiac troponin and symptoms indicative of acute coronary syndrome, the prevalence of type 2 myocardial infarction (type 2 AMI) has a wide variability, ranging from 1.6–71% [52]. Type 2 AMI more frequently occurs among older patients with numerous comorbid conditions [52,53] and is associated with a poor long-term outcome [54]. In type 2 AMI, a comorbid condition (e.g., sustained tachyarrhythmia, atrial fibrillation (AF), severe hypertension, respiratory failure, severe anemia or shock) is the major contributor of a significant imbalance between myocardial oxygen supply and/or demand with consequent cardiac troponin elevation [55].…”

Section: St2 In Acute Myocardial Infarctionmentioning

confidence: 99%

Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone

Aleksova

Paldino

Beltrami

et al. 2019

JCM

View full text Add to dashboard Cite

Soluble ST2 (sST2) has recently emerged as a promising biomarker in the field of acute cardiovascular diseases. Several clinical studies have demonstrated a significant link between sST2 values and patients’ outcome. Further, it has been found that higher levels of sST2 are associated with an increased risk of adverse left ventricular remodeling. Therefore, sST2 could represent a useful tool that could help the risk stratification and diagnostic and therapeutic work-up of patients admitted to an emergency department. With this review, based on recent literature, we have built sST2-assisted flowcharts applicable to three very common clinical scenarios of the emergency department: Acute heart failure, type 1, and type 2 acute myocardial infarction. In particular, we combined sST2 levels together with clinical and instrumental evaluation in order to offer a practical tool for emergency medicine physicians.

show abstract

Section: St2 In Acute Myocardial Infarctionmentioning

confidence: 99%

Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone

Aleksova

Paldino

Beltrami

et al. 2019

JCM

View full text Add to dashboard Cite

show abstract

“…Finally, the optimal medical treatment of T2MI is still unknown, since therapeutic agents currently used for type 1 MI have not been tested in T2MI so far. 6,[9][10][11] Accordingly, in our study we observed a very low use of such pharmacological treatments in COVID-19 patients.…”

Section: 000 Laboratory Valuesmentioning

confidence: 43%

“…However, cardiac catheterization almost certainly is associated with significant risk in such critically ill patients. Finally, the optimal medical treatment of T2MI is still unknown, since therapeutic agents currently used for type 1 MI have not been tested in T2MI so far 6,9–11 . Accordingly, in our study we observed a very low use of such pharmacological treatments in COVID-19 patients.…”

Section: Commentmentioning

confidence: 55%

Type 2 myocardial infarction in patients with coronavirus disease 2019

Talanas

Dossi

Parodi

2020

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

“…[16][17][18] Interestingly, it was observed that patients with T2MI were less likely to undergo invasive angiography. 19 In order to assess if the presence (or the absence) of a culprit lesion could affect the outcome, we performed a survival analysis between patients with T1MI compared to those with T2MI, which showed no difference in the rate of adverse events (Supplemental Figure 4S, http://links.lww.com/ JCM/A415). In addition, the proportion of patients with T2MI was equally distributed between the 'defer' and 'perform' groups (Table 1).…”

Section: Discussionmentioning

confidence: 99%

Fractional flow reserve in patients with type 1 or type 2 non-ST elevation acute myocardial infarction

Arena

Caretta

Gistri

et al. 2021

Journal of Cardiovascular Medicine

View full text Add to dashboard Cite

Aims We assessed a combined strategy of fractional flow reserve (FFR) plus angiography in stratifying cardiovascular risk in patients with type 1 myocardial infarction (T1MI) or type 2 (T2MI) non-ST elevation acute myocardial infarction (NSTEMI).Methods A cohort of 150 NSTEMI patients were prospectively studied. Clinical and angiographic features guided the identification of T1MI vs T2MI and the treatment of culprit lesions. Subsequently, T1MI patients underwent FFR evaluation of nonculprit stenoses. In T2MI patients all angiographically significant stenoses were evaluated by FFR. FFR < 0.80 was an indication for revascularization. Based on FFR results, two groups were compared: patients with all lesions > -0.80 ('defer' group, n U 87) and those with at least one lesion <0.80 ('perform' group, n U 63). The primary end point was the composite of all-cause death, nonfatal MI and unplanned coronary revascularization.Results Median clinical follow-up was of 35 months (interquartile range 14-44). Primary end-point rates in the 'defer' and 'perform' groups were 14.5% and 30.0% at 12 months and 28% and 46% at 36 months, respectively (log-rank test: at 1 year, P U 0.007; at the end of follow-up P U 0.014). On multivariable analysis, chronic kidney disease (HR 3.50, 95% CI: 1.89-6.46, P U 0.0001) and FFR group ('perform' vs 'defer': HR 1.75 95% CI: 1.01-3.04, P U 0.046) were independent predictors of adverse events.Conclusions In NSTEMI patients, our results indicated that FFR combined with angiography allowed the treatment of nonfunctional significant lesions to be safely deferred and patient cardiovascular risk to be identified.

show abstract

Type 2 myocardial infarction

Cited by 21 publications

References 21 publications

Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone

Cardiac Biomarkers in the Emergency Department: The Role of Soluble ST2 (sST2) in Acute Heart Failure and Acute Coronary Syndrome—There is Meat on the Bone

Type 2 myocardial infarction in patients with coronavirus disease 2019

Fractional flow reserve in patients with type 1 or type 2 non-ST elevation acute myocardial infarction

Contact Info

Product

Resources

About